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Periodic assessment of gene expression for diagnosis and monitoring in rheumatoid
arthritis (RA) may provide a readily available and useful method to detect subclinical
disease progression and follow responses to therapy with disease modifying
anti-rheumatic agents (DMARDs) or anti-TNF-α therapy. We used quantitative real-time
PCR to compare peripheral blood gene expression profiles in active (“unstable”) RA
patients on DMARDs, stable RA patients on DMARDs, and stable RA patients treated
with a combination of a disease-modifying anti-rheumatoid drug (DMARD) and an
anti-TNF-α agent (infliximab or etanercept) to healthy human controls. The expression of
48 inflammatory genes were compared between healthy controls (N = 122), unstable
DMARD patients (N = 18), stable DMARD patients (N = 26), and stable patients on
combination therapy (N = 20). Expression of 13 genes was very low or undetectable in
all study groups. Compared to healthy controls, patients with unstable RA on DMARDs
exhibited increased expression of 25 genes, stable DMARD patients exhibited increased
expression of 14 genes and decreased expression of five genes, and combined therapy
patients exhibited increased expression of six genes and decreased expression of 10
genes. These findings demonstrate that active RA is associatedwith increased expression
of circulating inflammatory markers whereas increases in inflammatory gene expression
are diminished in patients with stable disease on either DMARD or anti-TNF-α therapy.
Furthermore, combination DMARD and anti-TNF-α therapy is associated with greater
reductions in circulating inflammatory gene expression compared to DMARD therapy
alone. These results suggest that assessment of peripheral blood gene expression may
prove useful to monitor disease progression and response to therapy.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune,
inflammatory disorder that affects approximately 1% of the pop-
ulation in the United States (Lee and Weinblatt, 2001). Among
RA patients, the severity of disease, the spectrum of clinical
involvement and the response to therapy vary widely, resulting
in significant diagnostic and management challenges. RA is cur-
rently monitored via repeated clinical assessment of specific signs
and symptoms, and by a variety of blood and radiological tests.
Unfortunately, none of the clinical laboratory tests in use today
can reliably assess disease activity or predict flares of disease or
the extent of underlying joint damage.
RA is characterized by chronic inflammation and hyper-
trophy of the synovial membranes. Inflammation of the joint
occurs in response to production of growth factors, cytokines,
and chemokines by many different cell types present in syn-
ovium and cartilage, in addition to infiltrating cells from the
peripheral blood. Cartilage and bone destruction subsequently
occur through the enhanced actions of prostaglandins, leuko-
trienes, and the matrix degrading metalloproteinases (MMPs).
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The importance of interleukin-1 (IL-1) and tumor necrosis
factor-α (TNF-α) in animal models of RA is well documented
(Saklatvala, 1986; Issekutz et al., 1994; Hata et al., 2004). TNF-α
is known to stimulate IL-1 and interleukin-6 (IL-6) production
in synovial tissue (Pettipher et al., 1986; Brahn et al., 1992).
These cytokines enhance migration of inflammatory cells into the
joint and stimulate MMP production in synovial fibroblasts and
chondrocytes (Pettipher et al., 1986).
Although the most important actions of these proteins are
likely to occur in the joint, the joint space is relatively inacces-
sible, prohibiting quantitative measurement of cytokines. Recent
advances in the clinical application of pharmacogenomics sug-
gest that biomarkers of disease activity and drug efficacy can be
identified in blood to enable the identification of specific patient
populations and to monitor subclinical changes in disease sta-
tus and responses to treatment over time (Frank and Hargreaves,
2003; McLoughlin et al., 2006; Luo et al., 2011). Changes in
the serum levels of several proteins have been observed in RA
patients: cytokines such as IL-1α, IL1-β, IL-6, IL-10, and TNF-α
are increased in RA compared to normal (Deane et al., 2010;
Milman et al., 2010); and intercellular adhesion molecule-1
(ICAM-1) level is increased in juvenile RA compared to normal
(Bloom et al., 2005; Ishikawa et al., 2009). Factors such as protein
instability and sampling variability may, however, limit analyses
of serum protein expression. Because altered gene expression pre-
cedes release of cytokines and other immunologically important
signaling elements, analysis of specific messenger RNA (mRNA)
species associated with these changes will provide the earliest
diagnostic signs of disease progression and/or flare. Blood sam-
ples from patients with RA have been studied by microarray
to profile complex expression patterns of genes contributing to
inflammatory joint disease (Bovin et al., 2004; Olsen et al., 2004;
Batliwalla et al., 2005; Edwards et al., 2007; van der Pouw Kraan
et al., 2007; Ishikawa et al., 2009; Teixeira et al., 2009; Deane et al.,
2010).
We have previously shown that among healthy volunteers,
expression of a number of inflammatory genes can be accurately
measured by quantitative reverse transcriptase PCR (qRT-PCR)
from peripheral blood samples collected over time, and that
this expression is relatively stable (McLoughlin et al., 2006).
Importantly, these data suggest that normal reference ranges can
be established for the expression of a broad set of inflammatory
genes in human whole blood. Here, we use qRT-PCR to measure
inflammatory gene expression in whole blood obtained at a sin-
gle time point from RA patients with either active (“unstable”)
or stable disease on DMARD therapy, and patients with stable
disease on combination therapy with a DMARD and anti-TNF-α
agent (“combination”), and compared the changes in inflamma-
tory gene expression in these groups to levels in whole blood
obtained from healthy controls.
MATERIALS AND METHODS
SUBJECT CHARACTERISTICS
Samples from blood donor subjects were collected for the current
study with approval of the University of Colorado Institutional
Review Board and after obtaining written consent from each
volunteer. Whole blood samples were collected at a single time
point from 122 apparently healthy blood donors at a local blood
bank (Bonfils Blood Center, Denver, CO). Enrollment criteria for
blood donors followed the American Red Cross donor standards.
Subject age was normally distributed and ranged from 22 to 82
years, with an average age of 47.2 ± 13.1 years. Females (N = 63)
and males (N = 59) were represented in about equal numbers,
and 82% of the subjects were Caucasian. RA patients eligible for
the study met the following inclusion criteria: (1) diagnosis of
RA according to the American College of Rheumatology 1987
diagnostic criteria (Arnett et al., 1988); (2) 18 years of age or
older; (3) subjects with “stable” RA as defined by presence or
history of moderate to severe RA on stable doses for the pre-
vious 3 months of DMARDs, NSAIDs, or oral corticosteroids
(≤10mg/day of prednisolone or equivalent); and (4) subjects
with “unstable” active RA as defined by 6 or more swollen joints
or 9 or more painful or tender joints at baseline and C-reactive
protein (CRP) ≥2mg/dL at the initial visit and who required
more aggressive therapy. Exclusion criteria included: (1) any pre-
vious treatment with a non-DMARD immunosuppressive drug;
(2) use of any investigational drug or biological agent (except
anti-TNF-α therapies) within 3 months prior to enrollment; (3)
previous diagnosis of any acute or chronic infectious disease, or
with current signs or symptoms of severe, progressive, or uncon-
trolled systemic disease; (4) pregnancy; (5) history of malignancy
in the 5 years prior to study enrollment; or (6) ACR functional
class IV. In addition to collection of whole blood samples, phys-
ical examination, physician assessment of disease activity and
morning stiffness, patient assessment of disease and pain activ-
ity, and joint assessment (based on a 66/68-joint count excluding
distal interphalangeal joints) were performed at baseline and at
12 weeks after initiation of anti-TNF-α therapy (or continuation
of previous DMARD therapy in stable RA patients).
Using the criteria described above, there were three exper-
imental patient subpopulation groups: (1) RA patients who
were on a systemic disease-modifying anti-rheumatoid drug
(DMARD, either oral prednisone or oral methotrexate), with
active disease and judged by their physician to require a change
in therapy (“unstable”) (N = 18); (2) RA patients receiving
DMARD therapy for more than 3 months and judged by their
physicians not to require a change in therapy (“stable”) (N = 26);
and (3) clinically stable RA subjects treated for more than 3
months with a DMARD plus one of two different anti-TNF-α
therapies (infliximab or etanercept) and judged by their physician
not to require a change in therapy (“combination”) (N = 20).
Characteristics of each experimental patient group are shown in
Table 1.
PREPARATION OF NUCLEIC ACIDS AND QUANTITATIVE PCR ANALYSIS
Blood was collected from study subjects by standard phlebotomy
methods into PAXgene™ tubes (PreAnalytiX, Valencia, CA) to
stabilize mRNA levels. Samples were frozen at−70◦C and shipped
on dry ice in compliance with International Air Transport
Association (IATA) shipping regulations. Total RNAwas extracted
as described previously using the PAXgene™ Blood RNA System
(Rainen et al., 2002). The purity and integrity of each RNA sam-
ple was determined and the mRNA was converted to cDNA by
reverse transcription (Rainen et al., 2002). First-strand cDNAwas
Frontiers in Immunology | Inflammation December 2012 | Volume 3 | Article 366 | 2
Edwards et al. Whole blood gene expression in RA
Table 1 | Clinical features of RA patient subpopulation groups tested
for qRT-PCR analysis.
Clinical feature Unstable on
DMARD
(n = 18)
Stable on
DMARD
(n = 26)
Stable on
combination
therapy
(n = 20)
Gender (% female) 79 61 85
Age (years) 54.1 55.8 57.7
Race (% white,
non-Hispanic)
67 50 90
Duration of disease
(months)
220 200 227
DMARD use (%) 75 100 100
Prednisone use (%) 64 75 25
MTX weekly dose (mg) 15.5 9.95 14.5
See “Materials and Methods” section for details on patient background and
selection.
synthesized from randomhexamer-primed RNA templates on the
ABI Prism™ 6700 Nucleic Acid Automated Workstation using
TaqMan® Reverse Transcription Reagents (Applied Biosystems,
Multiscribe #4311235, Foster City, CA), according to the man-
ufacturer’s procedure.
Target gene products were analyzed by quantitative PCR of
each cDNApreparation using 2X TaqMan®Universal PCRMaster
Mix (Applied Biosystems, #4305719, Foster City, CA) and Source
Precision Medicine’s proprietary primer/probe sets and adher-
ing to previously described protocols (McLoughlin et al., 2006).
Forty-eight inflammation- and immune-related gene products
that were originally selected and verified (McLoughlin et al.,
2006) were analyzed with slight modification (Table 2). For
example, apoptotic protease activating factor 1 (APAF1) and
Cytochrome B-245 beta polypeptide (CYBB) were replaced with
transforming growth factor beta 1 (TGFB1, a pro- and anti-
inflammatory cytokine) and vascular endothelial growth factor
(VEGF, an inducer of angiogenesis) because of their involvement
in inflammation and the pathogenesis of RA (Kasama et al., 2001;
Mattey et al., 2005). Reactions were run in four replicates on
an ABI Prism 7700 Sequence Detection System. The amount of
cDNA added to each reaction was held to a narrow range, within
1.5 CT’s, based on the threshold cycle (CT) of the 18S RNA control
reaction. The coefficient of variation in the CT values detected for
each gene loci were less than 2% in a study that consisted of more
than 1000 repeat analyses of the same freezer-stored sample. The
repeat analyses were performed over greater than a 2-year period.
DATA ANALYSIS
Each PCR reaction contained primer/probe sets for the target
gene and 18S RNA, used as the internal control. The differ-
ence between the fluorescence CT for the target and the internal
endogenous control (18S) is presented as a CT value. Increases
or decreases in the target mRNA concentration correspond to
lower or higher CT values, respectively, at approximately 2-fold
concentration change per CT unit. The CT reporting system
and estimation of relative gene expression is well described in
the literature (Livak and Schmittgen, 2001). CT values above 23
should be interpreted with caution, because they correspond to
gene expression levels at or below the linear range of the assay.
Statistical measures were determined using Enterprise Guide
version 2.05.89 (SAS Institute, Inc., Cary, NC). The Anderson-
Darling test and the Shapiro-Wilk test were used to determine
whether the gene expression data fit a normal distribution.
Student’s t-tests were performed to determine P values.
RESULTS
ALTERED GENE EXPRESSION IN UNSTABLE RA PATIENTS COMPARED
TO HEALTHY SUBJECTS
Gene expression levels were measured in whole blood sam-
ples collected from 18 unstable patients with RA maintained on
DMARD therapy. Of a total of 48 gene products analyzed, 13
demonstrated very low or undetectable levels among the study
subjects. These genes (CSF2, CSF3, CXCL2, F3, IL1A, IL2, IL4,
IL6, IL12B, IL13,MMP3, NOS2A, and PLAUR) were not included
in further analysis. Of 35 inflammation-related genes examined,
these unstable RA patients exhibited increased expression of 25
genes (B7, C1QA, CD14, CD19, CD4, CD8A, CXCL1, HMOX1,
HSPA1A, ICAM1, IL10, IL15, IL18, IL18BP, IL1RN, IL1B, MMP9,
PTGS2, PTPRC, SERPINE1, TGFB1, TIMP1, TNF, TNFSF13B,
TNFSF6, and VEGF) and decreased expression of 1 gene (CD19)
compared to healthy controls (P < 0.05) (Table 3, Figure 1A).
MMP9, HSPA1A, SERPINE1, and TGFB exhibited the greatest
increases in mean level of expression in RA patients compared
to healthy subjects. Changes in expression of each individual
gene averaged over all patients in the unstable RA patient group
and compared to average gene expression in the healthy control
population are depicted in Figure 1A.
CHANGES IN GENE EXPRESSION DURING DMARD THERAPY
Whole blood was collected from 26 RA patients with sta-
ble clinical examinations after at least 12 weeks of DMARD
therapy. Serum levels of CRP in these patients ranged from
0.05 to 2.7mg/L (average 0.35mg/L), consistent with low sys-
temic levels of inflammation. Of 35 inflammation-related genes
examined, stable RA patients maintained on DMARD ther-
apy exhibited increased expression of 14 genes (CD14, CXCL1,
HMOX1, HSPA1A, ICAM1, IL18, IL1RN, IL1B, MMP9, PTGS2,
PTPRC, TGFB1, TIMP1, and TNFSF13B) and decreased expres-
sion of 5 genes (CD19, CD3Z, HLA-DRB1, TNFRSF13B,
and VEGF) compared to healthy controls (P < 0.05) (Table 3,
Figure 1B). Expression of B7, C1QA, CD4, CD8A, IL10, IL15,
IL18BP, SERPINE1, TNF, and TNFSF6 were normalized com-
pared to unstable RA patients maintained on DMARD therapy
(Figures 1A,B).
CHANGES IN GENE EXPRESSION DURING COMBINATION THERAPY
Whole blood was collected from 20 RA patients with stable
clinical examinations after 12 weeks of treatment with combi-
nation therapy (a DMARD and an anti-TNF-α agent). Of 35
inflammation-related genes examined, 6 genes (C1QA, CD4,
HMOX1, IL15, IL8, and TNFSF13B) exhibited increased expres-
sion and 11 genes (B7, CD19, CXCL1, IFNA2, IL10, IL18BP,
IL1RN, IL5, PTGS2, TNFRSF13B, and TNFSF5) demonstrated
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Table 2 | List of 48 inflammatory genes analyzed in the study and mean CT of gene expression in healthy subjects.
HUGO
designation
Gene name Gene function Mean CT of healthy
subjects (n = 122)
B7 CD80 Regulatory protein that may be associated with lupus 21.17
C1QA Complement component 1,
q subcomponent, A chain
Serum complement system component, forms C1 complex with
pro-enzymes C1r and C1s
21.64
CD3Z CD247 molecule T-cell surface glycoprotein 15.20
CD4 CD4 molecule Helper T-cell marker; accessory protein in the MHC/T-cell
receptor interaction
15.84
CD8A CD8a molecule Cytotoxic/suppressor T-cell marker; binds MHC I; thought to play
role T-cell mediated killing
16.40
CD14 CD14 molecule Monocyte LPS receptor; cooperates with MD-2 and TLR-4 in
response to LPS
14.84
CD19 CD19 molecule B-cell growth factor; membrane protein that potentiates
receptor-dependent activation
18.65
CXCL1 Chemokine (C-X-C motif)
ligand 1
Chemotactic for neutrophils; pro-inflammatory; modulates
metalloproteinase activity
19.78
CXCL2 Chemokine (C-X-C motif)
ligand 2
Chemotactic for neutrophils and hematopoietic precursor cells 23.32
CSF2 Colony stimulating factor 2 aka GM-CSF; stimulates growth and differentiation of
hematopoietic precursor cells
23.59
CSF3 Colony stimulating factor 3 aka GCSF; cytokine that stimulates granulocyte development 23.45
F3 Coagulation factor 3
(thromboplastin, tissue factor)
aka thromboplastin, coagulation factor 3; responsible for
coagulation catalysis
23.63
HLA-DRB1 Major histocompatibility
complex, class II, DR beta 1
Binds antigen for presentation to CD4+ cells 22.09
HMOX1 Heme oxygenase (decycling) 1 Essential for heme catabolism; cleaves heme to form biliverdin
and CO; endotoxin inducible
17.10
HSPA1A Heat shock protein A1A Molecular chaperone; stabilizes AU rich mRNA; hydrophobic
peptide
14.76
ICAM1 Intercellular adhesion
molecule 1
Endothelial cell surface molecule; regulates cell adhesion and
trafficking of leukocytes
18.05
IFNA2 Interferon, alpha 2 Interferon produced by macrophages with antiviral effects 22.20
IFNG Interferon gamma Pro- and anti-inflammatory activity, TH1 cytokine, inflammatory
mediator of activated T-cells
22.98
IL1A Interleukin-1, alpha Pro-inflammatory; generally cytosolic, released during severe
inflammatory disease
23.14
IL1B Interleukin-1, beta Pro-inflammatory; made by activated macrophages; endogenous
pyrogen
16.19
IL1RN Interleukin-1 receptor
antagonist
Anti-inflammatory; inhibits binding of IL-1 its receptor without
stimulating IL-1 activity
16.41
IL2 Interleukin-2 T-cell growth factor, expressed by activated T-cells, TH1 cytokine 23.11
IL4 Interleukin-4 Anti-inflammatory; TH2; suppresses cytokines, increases IL-1RN
expression
23.25
IL5 Interleukin-5 Stimulates eosinophil expansion and B-cell differentiation 22.70
IL6 Interleukin-6 Pro- and anti-inflammatory activity; TH2 cytokine; regulates
hematopoiesis
23.11
IL8 Interleukin-8 Pro-inflammatory CXC chemokine; major secondary
inflammatory mediator
21.04
IL10 Interleukin-10 Anti-inflammatory; TH2 cytokine; suppresses production of
pro-inflammatory cytokines
22.84
IL12B Interleukin-12b Pro-inflammatory, TH1 cytokine, requires co-stimulation with
IL-18 to induce IFN-γ
23.28
IL13 Interleukin-13 Inhibits inflammatory cytokine production 23.09
IL15 Interleukin-15 Pro-inflammatory; T-cell activator; inhibits apoptosis; with IL-2
induces IFN-γ and TNF-α
22.05
(Continued)
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Table 2 | Continued
HUGO
designation
Gene name Gene function Mean CT of healthy
subjects (n = 122)
IL18 Interleukin-18 Pro-inflammatory; TH1 cytokine; promotes apoptosis;
induces IFNγ; blocked by IL18BP
20.12
IL18BP Interleukin-18 binding protein Binds and inactivates IL18; implicated in inhibition of
early TH1 cytokine responses
17.59
MMP3 Matrix metallopeptidase 3 aka stromelysin; degrades fibronectin, laminin, and
gelatin
23.71
MMP9 Matrix metallopeptidase 9 Degrades extracellular matrix molecules; made by
neutrophils; Role in arthritis and metastasis
16.39
PLA2G7 Phospholipase A2, group VII Activates platelet activating factor (PF4) 19.93
NOS2A Nitric oxide synthase 2a, inducible aka iNOS; produces NO which is
bacteriocidal/tumoricidal
23.53
PLAUR Plasminogen activator, urokinase receptor Ligand-specific cell surface receptor for UPA; localizes
and promotes plasmin formation
15.59
PTGS2 Prostaglandin-endoperoxide synthase 2 Pro-inflammatory; regulates angiogenesis and cell
migration
17.92
PTPRC Protein tyrosine phosphatase,
receptor type, C
An essential regulator of T- and B-cell antigen
receptor signaling; suppresses JAK kinases
11.89
SERPINE1 Serpin peptidase inhibitor, clade E Interacts with tissue plasminogen activator to
regulate fibrinolysis; inhibits PLAU
22.95
TGFB1 Transforming growth factor, beta 1 Pro- and anti-inflammatory activity; anti-apoptotic 13.55
TIMP1 TIMP metallopeptidase inhibitor 1 Inhibitors of matrix metalloproteinases;
transcriptionally induced by cytokines and hormones
15.11
TNF Tumor necrosis factor Pro-inflammatory TH1 cytokine, primary mediator of
immune response and regulation
20.65
TNFSF5 CD40 ligand Ligand for CD40; expressed on T-cells; regulates
B-cell function by engaging CD40
17.61
TNFSF6 Fas ligand (TNF superfamily, member 6) Ligand for FAS antigen; critical in triggering apoptosis 21.00
TNFSF13B Tumor necrosis factor (ligand) superfamily,
member 13b
B cell activating factor, TNF family 15.46
TNFRSF13B Tumor necrosis factor receptor superfamily,
member 13b
Controls T-cell-dependent B-cell antibody responses 20.81
VEGF Vascular endothelial growth factor Produced by monocytes 23.07
decreased expression compared to healthy controls (P < 0.05)
(Table 3, Figure 1C). The increased expression of 15 genes
present in the unstable RA patient group on DMARD therapy
was normalized in stable RA patients on combination therapy
(Figures 1A,C). These genes included CD14, CD8A, HSPA1A,
ICAM1, IL18, IL1B, MMP9, PTPRC, SERPINE1, TGFB1, TIMP1,
TNF, and TNFSF6.
Among 20 patients receiving combination therapy, patients
receiving infliximab (N = 10) exhibited decreased expression of
seven genes (B7, CXCL1, IL10, IL1RN, IL5, PTPRC, and TNFSF5)
and increased gene expression of one gene (C1QA) compared to
healthy controls, whereas patients receiving etanercept (N = 10)
exhibited increased expression of three genes (HMOX1, IL8, and
TNFSF13B) and decreased expression of nine genes (CD8A, IL10,
IL18BP, IL1RN, IL5, PTGS2, PTPRC, TNFRSF13B, and TNFSF5
compared to healthy controls (P < 0.05) (Table 4). RA patients
stable on etanercept exhibited robust increases in IL8 expres-
sion (5.70-fold change compared to healthy controls, P < 0.0001,
Table 4).
DISCUSSION
Identification of easily accessible and reliable biomarkers of
inflammatory disease activity to diagnose and monitor disease
progression in individual patients over time is an attractive thera-
peutic goal. Here, we demonstrate that gene expression analysis of
whole blood using qRT-PCR can be used to assess disease activity
of RA patients.
Patients with unstable RA demonstrated increased periph-
eral blood expression of numerous proinflammatory cytokines,
including IL1B, TNF, and IL18, and increased expression of genes
whose protein products have been shown to contribute to syn-
ovial deterioration (includingMMP) compared to healthy human
control subjects. These cytokines have been previously shown
to be upregulated in the synovium or serum in RA (Brennan
et al., 1992; Gracie et al., 1999; Feldmann and Maini, 2001;
Joosten et al., 2004; Klimiuk et al., 2004; Paramalingam et al.,
2007; Shao et al., 2009; Volin and Koch, 2011). In compari-
son, increases in inflammatory gene expression are diminished in
patients with stable disease on either DMARD alone or combined
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Table 3 | Single time point gene expression analysis in RA patients unstable on DMARD therapy, stable on DMARD therapy, and stable on
combination therapy.
Gene name Relative expression (fold change)a P valueb
Unstable on
DMARD
(n = 18)
Stable on
DMARD
(n = 26)
Stable on
anti-TNF
(n = 20)
Unstable on
DMARD
(n = 18)
Stable on
DMARD
(n = 26)
Stable on
anti-TNF
(n = 20)
B7 1.24 1.07 0.75 0.0475 0.5217 0.0100
C1QA 2.42 1.10 1.52 <0.0001 0.5567 0.0251
CD14 2.25 1.47 1.10 <0.0001 0.0006 0.3615
CD19 0.64 0.54 0.68 0.0090 <0.0001 0.0132
CD3Z 1.01 0.81 0.89 0.9495 0.0160 0.1683
CD4 1.47 1.13 1.04 0.0012 0.2490 <0.0001
CD8A 1.54 0.87 0.81 0.0062 0.3299 0.1707
CXCL1 1.89 1.43 0.75 <0.0001 0.0016 0.0263
HLA-DRB1 0.69 0.32 0.92 0.4900 0.0379 0.9067
HMOX1 2.25 1.49 1.30 <0.0001 0.0003 0.0385
HSPA1A 2.62 1.77 1.15 <0.0001 <0.0001 0.2548
ICAM1 2.25 1.44 1.07 <0.0001 0.0003 0.5007
IFNA2 1.25 1.06 0.62 0.1295 0.7230 0.0004
IFNG 1.24 0.84 ND 0.0614 0.0795 *
IL10 1.34 0.93 0.61 0.0206 0.5005 <0.0001
IL15 1.43 0.94 1.33 0.0095 0.6242 0.0447
IL18 2.14 1.41 1.09 <0.0001 0.0010 0.4815
IL18BP 1.60 1.18 0.78 <0.0001 0.0644 0.0025
IL1RN 2.48 1.84 0.68 <0.0001 <0.0001 0.0006
IL1B 2.24 1.69 0.93 <0.0001 <0.0001 0.5218
IL5 1.26 0.97 0.61 0.0857 0.8539 <0.0001
IL8 1.01 1.06 2.69 0.9721 0.7469 <0.0001
MMP9 3.45 2.04 1.19 <0.0001 0.0001 0.3469
PLA2G7 1.14 0.92 0.92 0.4591 0.5298 0.6262
PTGS2 2.23 1.26 0.78 <0.0001 0.0248 0.0136
PTPRC 1.49 1.25 0.67 <0.0001 0.0138 0.6788
SERPINE1 2.56 1.21 1.12 <0.0001 0.1680 0.4726
TGFB1 2.52 1.59 0.96 <0.0001 <0.0001 0.5757
TIMP1 2.02 1.35 1.08 <0.0001 0.0010 0.4304
TNF 1.90 1.11 0.88 <0.0001 0.3426 0.3158
TNFRSF13B 0.80 0.61 0.60 0.1674 0.0004 0.0028
TNFSF13B 1.97 1.35 1.47 <0.0001 0.0137 0.0017
TNFSF5 1.17 0.97 0.62 0.1691 0.7831 <0.0001
TNFSF6 1.70 0.79 0.93 0.0008 0.0839 0.6686
VEGF 1.38 0.84 ND 0.0028 0.0474 *
aCT values of genes expressed in RA subjects were compared to those from healthy blood donors.
bProbability of a difference between groups was determined by Student’s t-test. P value represents comparison of gene expression from healthy blood donors.
ND indicates data not determined.
∗Indicates statistics not analyzed.
Bold values are statistically significant P values.
DMARD and anti-TNF-α therapy. These results indicate that
clinical assessments of overall disease stability correlate with an
overall reduction in peripheral inflammatory gene expression.
Unstable RA patients in the current study also exhibited
increased expression of several cytokines which are generally
thought to have an anti-inflammatory effect, including IL10,
IL1RN, and TGFB1 (Katsikis et al., 1994). These have been
reported to be elevated in the synovium and in periph-
eral blood samples from RA patients (Katsikis et al., 1994;
Ohshima et al., 1999; Mesko et al., 2010; Tukaj et al., 2010;
Meugnier et al., 2011), where they may serve to mitigate
the inflammatory process. Further, expression of IL10 and
IL1RN in stable RA patients on either DMARD or com-
bination DMARD and anti-TNF-α therapy was the same
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FIGURE 1 | Relative fold-changes in whole blood gene expression in RA
patients compared to healthy controls. (A) Unstable RA patients on
DMARD therapy (n = 18). (B) Stable RA patients on DMARD therapy
(n = 26). (C) Stable RA patients on combined DMARD and anti-TNF-α therapy
(n = 20). Changes in expression for each individual gene are averaged and
compared to healthy controls. Significant changes in gene expression
(P < 0.05) are depicted as closed bars, and non-significant changes in gene
expression are depicted as open bars.
(DMARD) or reduced (combination) compared to healthy con-
trols (Table 3). It is speculated that as levels of proinflamma-
tory cytokines are reduced during effective anti-TNF-α therapy,
corresponding levels of anti-inflammatory cytokines are also
reduced.
Our data, however, also demonstrate that despite stable clin-
ical assessments, RA patients on DMARD therapy alone con-
tinue to exhibit increased expression of some inflammatory
genes, suggesting that subclinical inflammation is still present
in these patients. Stable RA patients on combination therapy
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Table 4 | Single time point gene expression analysis of stable RA
patients on DMARD therapy and anti-TNF-α therapy with either
infliximab or etanercept.
Gene Relative expression P valueb
name (fold change)a
Stable on
infliximab
(n = 10)
Stable on
etanercept
(n = 10)
Stable on
infliximab
(n = 10)
Stable on
etanercept
(n = 10)
B7 0.67 0.92 0.0024 0.4999
C1QA 2.02 0.99 0.0014 0.9696
CD14 1.14 1.04 0.3689 0.7978
CD3Z 0.89 0.94 0.2948 0.5865
CD4 1.03 1.06 0.8423 0.6788
CD8A 1.04 0.58 0.8418 0.0063
CXCL1 0.68 0.79 0.0284 0.1727
HMOX1 1.26 1.40 0.1278 0.0451
HSPA1A 1.15 1.09 0.3865 0.5708
ICAM1 0.98 1.13 0.8911 0.3179
IL10 0.68 0.64 0.0183 0.003
IL15 1.43 1.20 0.0555 0.3005
IL18 0.90 1.25 0.4656 0.0925
IL18BP 0.82 0.73 0.0526 0.003
IL1RN 0.61 0.73 0.0014 0.0203
IL1B 0.78 1.07 0.078 0.6039
IL5 0.66 0.46 0.0101 <0.0001
IL8 1.50 5.70 0.1585 <0.0001
MMP9 1.20 1.06 0.461 0.7911
PLA2G7 0.86 1.07 0.4403 0.7478
PTGS2 0.82 0.71 0.1617 0.012
PTPRC 0.75 0.63 0.0123 <0.0001
SERPINE1 1.21 0.94 0.286 0.7372
TGFB1 1.02 0.88 0.8391 0.1836
TIMP1 1.02 1.10 0.8459 0.4071
TNF 0.83 0.81 0.2149 0.1582
TNFRSF13B 0.76 0.51 0.1389 0.0004
TNFSF13B 1.37 1.49 0.0592 0.0117
TNFSF5 0.59 0.62 0.0002 0.001
TNFSF6 1.09 0.75 0.6164 0.102
aCT values of genes expressed in RA subjects were compared to those from
healthy blood donors.
bProbability of a difference between groups was determined by Student’s t-test.
P value represents comparison of gene expression from healthy blood donors.
Bold values are statistically significant P values.
demonstrate a greater reduction in inflammatory gene expres-
sion compared to both unstable and stable RA patients on
DMARD alone. Specifically, patients on combination therapy
exhibit fewer increases in proinflammatory markers compared to
patients on DMARD alone, and decreased expression of a num-
ber of proinflammatory genes even compared to healthy controls.
Our findings suggest that even when chronic inflammatory dis-
ease is clinically stable, inflammatory pathways may still be active.
These pathways could contribute to long-term development of
comorbidities associated with RA. Further, variations in the
inflammatory profile differ in patients on DMARD alone versus
combined DMARD and anti-TNF-α therapy, and combination
therapy appears to confer a greater overall anti-inflammatory
effect compared to DMARD therapy. Whether changes in the
expression of particular genes may be useful biomarkers to assess
overall disease activity remains to be determined, and is an area
of ongoing research.
Changes in gene expression with anti-TNF-α therapy were
largely similar between patients receiving infliximab and etaner-
cept, with the notable exception of significantly increased expres-
sion of the chemokine IL8 in patients on etanercept compared
to healthy controls and to RA patients on DMARD or inflix-
imab therapies (Table 3). IL8 recruits neutrophils and T cells to
the synovium and stimulates angiogenesis (reviewed in Badolato
and Oppenheim, 1996). The mechanisms and long-term con-
sequences of IL8 induction during anti-TNF-α treatment are
unclear and further studies are warranted.
Despite variable disease activity and treatment modalities,
the expression of several proinflammatory genes was increased
among all three experimental groups compared to healthy con-
trols, including HMOX1 and TNFSF13B (Table 3). HMOX1 is
a heme oxygenase that reduces levels of the pro-oxidant heme
to reduce overall oxidative stress. Its expression is induced by a
variety of noxious stimuli, including hypoxia, inflammation, and
environmental stressors (Otterbein et al., 2003). TNFSF13B is
increased by TNF-α and IFN-γ in the synovium (Alsaleh et al.,
2007; Assi et al., 2007; Woo et al., 2011). Sustained elevations
of these genes may be associated with the inflammation in the
synovium and serum during the development and progression of
RA. TNFSF13B is also known as B-cell activating factor (BAFF).
Increased TNFSF13B can be contrasted with the expression of
CD19, a marker of B cells, which was consistently suppressed rel-
ative to healthy controls among all three RA groups, as has been
previously reported (Holden et al., 2011).
Assessment of peripheral blood gene expression provides an
easily accessible population of inflammatory cells in which to
study relative changes in cytokine expression over time. However,
it is important to consider that in any given individual, rela-
tive proportions of each blood cell type may vary markedly. In
this setting, overall changes in peripheral blood gene expression
may be significantly influenced by changes in the proportion of
blood cell types and their corresponding transcription profiles.
For example, we observed upregulation of CD14, a monocyte-
specific marker, in unstable RA patients treated with DMARD
(Table 3). CD14 expression was attenuated in stable RA patients
on DMARD therapy and was normalized in stable RA patients on
anti-TNF-α therapy (Table 3). In our unstable RA patient popula-
tion, therefore, an increased proportion of circulating monocytes
may have influenced the expression levels of some cytokines.
IL-6 is a proinflammatory cytokine that stimulates differ-
entiation of B-cells into antibody-producing plasma cells and
contributes to the release of metalloproteases from tissue fibrob-
lasts (Badolato and Oppenheim, 1996). Increases in IL-6 protein
levels in the synovium and the serum have been demonstrated
in RA patients, particularly associated with acute inflammation
early in the disease process (Houssiau et al., 1988; Hovdenes et al.,
1990; Madhok et al., 1993). Our results demonstrate very low or
undetectable levels of IL6 mRNA from peripheral blood cells of
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stable RA patients treated with DMARD therapy and in stable
RA patients treated with combination DMARD and anti-TNF-α
therapy, suggesting significant attenuation of the proinflamma-
tory cytokine cascade that contributes to the progression of RA.
Expression of IL-6 is tightly regulated, and changes in gene
transcription may precede measurable changes in protein secre-
tion (DeFuego and Remick, 1991). High serum levels of IL-6
despite low levels of IL6 mRNA expression within mononuclear
cells isolated from the peripheral blood and from the synovial
fluid in RA patients suggest that high circulating proinflamma-
tory cytokine levels do not necessarily reflect increases in gene
expression within inflammatory cell populations (Vazquez-Del
Mercado et al., 1999). Our study examines mRNA levels of IL6,
which may not correspond to circulating levels of the protein
product. IL-6 within the joint space is derived from synovial
fibroblasts (Park and Pillinger, 2007; Verweij and Vosslamber,
2012); high levels of circulating IL-6 may derive from tissues
rather than from circulating mononuclear cells. Finally, previous
studies have shown no differences in IL-6 protein or mRNA tran-
script levels between early, untreated RA patients and chronic RA
patients previously treated with DMARD (Vazquez-Del Mercado
et al., 1999). Methotrexate, for example, has been shown to
inhibit IL-6 production in peripheral blood cells (Aggarwal and
Misra, 2003). All three patient groups in the current study were
treated with DMARD therapy which may suppress gene expres-
sion of IL6 even in the setting of active clinical disease. Finally,
circulating levels of IL-6 follow a circadian rhythm in both
healthy subjects and RA patients (Knudsen et al., 2008; Perry
et al., 2009); differences in sampling time between patients in
this study may have impacted our measurement of IL6 levels
in the overall study population. Further investigation regarding
the significance of low levels of IL6 in these unstable patients is
warranted.
Herein, we show that reduction of inflammatory gene expres-
sion levels differ between stable patients on DMARD and com-
bined DMARD and anti-TNF-α therapies. Since most genes in
healthy subjects exhibit limited dynamic ranges of expression,
we believe that in our study populations, differences in gene
expression levels may reflect disease activity. The current find-
ings suggest that these peripheral blood biomarkers correlate with
clinical status, and may therefore provide adjunctive information
about the efficacy of various treatments for RA. These biomark-
ers may also allow for assessment of the efficacy of particular
RA treatments, including anti-TNF-α therapies. Future studies to
determine peripheral blood biomarkers that may predict individ-
ual patient responses to a particular systemic therapy may provide
assistance with clinical decision making.
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